Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second ...

BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic ...